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Simple Summary: Johne’s disease (JD) is an important disease affecting cows in the UK dairy
industry, as is lameness, and both cause milk production losses and cows losing weight. The aim
of this work was to see if cows with JD were more likely to be lame and if so, what the order of
occurrence of these two events is. We looked at the JD and lameness records of two farms and paired
98 JD cows (half of them with a high response to the test for JD) and compared them with herd
mates. We evaluated the timing and the proportion of lameness in JD-positive cows compared to
their controls and proportion of lameness before and after the first JD-positive test. JD cows turn
lame on average three months earlier and are lame 2.7 times more often than non-JD cows. Further,
high positive cows were 2.8 times more likely to develop lameness after JD diagnosis compared to
medium positive cows. Results of this study suggest that there is a link between JD and lameness
and that JD precedes lameness. The underlying mechanisms for this association remain unknown
and were not the scope of this study.
Abstract: Johne’s disease (JD) is an important disease affecting the UK dairy industry, as is cattle
lameness. An association between JD and lameness has been suggested; however, little evidence
exists to support this. The purpose of this study was to determine if cows affected by JD were more
likely to be lame and if so, what the temporal association is. Retrospective dairy cow mobility and
JD status (based on milk ELISA) data were obtained from two farms of 98 JD cows (49 high and 49
medium positive) and their matched controls. We evaluated the timing and the proportion of (chronic)
lameness in JD-positive cows versus controls and proportion of lameness before and after the first
ELISA positive test. Compared to their controls, JD cows are lame more often (Odds Ratio = 2.7
(95% Confidence Interval = 1.2–6.0) p = 0.017) and became lame on average three months earlier
(p = 0.010). High positive cows were more likely to develop lameness after seroconversion (OR = 2.8
(95% CI = 1.1–7.5), p = 0.038) versus medium positive cows. Results of this study suggest that there
is a link between JD and lameness and that JD precedes lameness. The underlying mechanisms for
this association remain unknown and were not the scope of this study.
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1. Introduction
Johne’s disease (JD) is caused by the gram positive, acid fast, intracellular organism Mycobacterium
avium subspecies paratuberculosis (MAP). Typically, cows get infected as young calves, with rates of infection
decreasing significantly with age and the main risk period for infection being the first 6 months of life [1,2].
Although most ruminants can be affected, it is of particular importance to dairy cows. Despite an early-life
infection, cows do not show clinical signs or subclinical losses until at least 2 years old; it is a chronic,
progressive, and ultimately fatal granulomatous enteritis [1,3,4].
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MAP is endemic to the dairy herd in the United Kingdom (UK); a survey with 225 randomly
selected dairy farms, stratified by region and herd size, identified a true herd prevalence of 68%
(95% CI: 61–76) in the national dairy herd [5]. No recent prevalence data are available of Johne’s at
individual cow level for the UK, but a study in abattoirs in the Southwest of England found 3.5% of
culled cows had evidence of subclinical JD [6]. Clinically, the disease causes chronic diarrhoea, weight
loss, and oedema, with clinical signs tending to manifest in the late stages of the disease [7].
Very few cows develop clinical signs, with estimates of only 3 in 10,000 showing clinical signs
every year in England and Wales [8]. Clinical and subclinical effects of JD impact directly and indirectly
through economic losses on dairy farms. In the UK, it was estimated that costs to a hypothetical
200-cow herd was in the region of £7000–£11,000 in losses forgone [4]. Losses are due to premature
culling, reduced milk production, and decreased slaughter value [9].
Upon initial oral exposure of the calf, MAP is incorporated into the mucosal lymphoid tissue,
the majority of which is located in the ileum. This explains the main site of lesions [7]. Here, MAP is
taken up by macrophages and a cell-mediated immune response is initiated, with the bacteria being
contained within microscopic granulomas [10,11]. Infected cows will remain in a subclinical stage of
infection for several years, with diffuse granulomatous lesions developing [7]. There appears to be
progression from cell-mediated immune response to a humoral mediated immune response with the
production of antibodies [12]. The humoral-based immune response is not protective against MAP
and precedes the excretion of MAP pathogens in the faeces. The presence of antibodies to MAP is the
evidence that the shift in immune response has occurred. The reasons or triggers for this change and,
hence, progression of MAP infection into JD is currently unclear, but underlying genetic factors and
exogenous stress factors such as parturition, malnutrition, or other diseases (e.g., mastitis, lameness)
have been theorised [13].
Diagnosis of JD can be performed using different methods. Common techniques include faecal
culture or polymerase chain reaction (PCR) and serum or milk antibody enzyme-linked immunosorbent
assay (ELISA). Although all of these tests have a specificity of above 90%, they are limited by low
sensitivity [14]. The sensitivity of a single milk ELISA test is relatively low for milking heifers, around
40%, but increases with age to 77.5% (95% CI: 71.0–82.9). In contrast to single tests, repeated milk
ELISA testing allows risk profiling of the dairy cows and has therefore become current practice to pick
up cows earlier, before becoming clinical, which allows improved calving management with the aim of
reducing transfer of MAP infections to the calves [15].
Whilst it is important to focus on JD and the direct consequences, as there is a substantial impact
on the UK dairy industry, links to other disease processes have been investigated. It has been shown
that cows seropositive for MAP are associated with a higher individual cow milk somatic cell count
and are believed to be more prone to mastitis [16,17]. There are also indications that JD decreases
fertility, with ELISA positive cows having on average 28 extra days open compared to seronegative
herd mates [18]. Reasons for the relationship are unknown at present; however, proposals include
negative energy balance (NEB) and reduced cellular immunity seen with Johne’s disease [13,16].
Anecdotally, it has been remarked that cows with JD are more likely to be lame than those not
affected. However, there is very limited scientific evidence to support this observation. Raizman
et al. [19] found that the most common clinical sign seen in cows with JD was lameness. Villarino
and Jordan [20] found that Johne’s disease-affected cows were five times more likely to be lame than
non-affected cows; however, the temporal association remains unclear.
Lameness is an important condition affecting cows. In terms of cost to the dairy industry, it is
second only to mastitis [21]. There are a wide range of causes of lameness, which can be divided into
infectious (e.g., digital dermatitis and foul) and non-infectious (e.g., sole ulcers or white line disease)
causes [22]. Current estimates in 2010 place the prevalence of lameness in the UK at roughly 36%;
this is an increase from 20.6% in 1990 [23,24]. It is due to the economic and welfare consequences
of lameness and increasing prevalence that there is an industry-wide desire and drive to reduce the
overall impact of lameness. Mobility scoring is a useful tool in assessing the status of cows in the
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herd [25]. The results of the scoring can be used to formulate action plans, generate treatment lists and
monitor herd level lameness.
As both Johne’s disease and lameness have a major impact on the UK dairy industry, it is therefore
important to understand if there is a (temporal) relationship between the two and what this relationship
signifies. This will further assist in improving animal welfare and minimising losses. The aim of
the study was to investigate potential links between Johne’s disease and lameness. This was done
by identifying whether cows with JD (milk ELISA positive) are more likely to be lame than matched
control (ELISA negative) cows and by determining the temporal sequence of events.
2. Materials and Methods
2.1. Cow Selection
Two farms in Southern England were selected for the study and consisted mainly of Holstein
Friesian cows which were milked twice daily. Herd A had 130 milking cows and herd B had 370 milking
cows. The farms are considered a convenience sample, and selection was based on the presence of
Johne’s disease on the farm, routine lameness recording and having quarterly milk ELISAs for MAP
tests done for at least one year. Mobility scoring on exit from the milking parlour was assessed on both
farms by the Royal Veterinary College using the Agriculture and Horticulture Development Board
(AHDB) Dairy 0–3 system [26]. In both herds, clinically lame cows were foot-trimmed therapeutically
on a monthly basis as well, and all cows were routinely foot-trimmed at dry-off.
Herd A block-calved in the autumn; all cows had pasture access during the summer with maize
silage buffer feed before daily turn-out. Winter ration consisted of 50%–50% maize- and grass silage
offered as a mixed ration. The cows were fed concentrates in the milking parlour. Average 305-day milk
yield was 7652 kg, with 4.21% fat, 3.34% protein and 148,000 cells/mL somatic cell count. Throughout
the year, copper sulphate footbaths were used three times a week, and mobility scoring took place
every month; clinical lameness was at an annual incidence rate of 21%.
Herd B calved year-round; low yielding cows had access to pasture in summer, whilst the high
yielders were in receiving 60%–40% maize- and grass silage offered as a mixed ration. The cows were
fed concentrates in the milking parlour. Average 305-day milk yield was 8710 kg, with 4.04% fat,
3.23% protein and 224,000 cells/mL somatic cell count. Formalin footbaths were used every two days
year-round, and lameness scoring was performed every two months; clinical lameness was at an annual
incidence rate of 13%.
Johne’s testing was performed on both farms by individual milk antibody ELISA through the
NMR HerdWise scheme. The test used was a commercial milk ELISA, produced by IDEXX; Pourquier
Mycobacterium paratuberculosis Screening Antibody Test [27] (IDEXX Laboratories Inc., Westbrook, ME).
The results were read following the manufacturer’s guidelines, using a cut-off of 20%: Tests with
a sample-to-positive ratio (S/P) of 20% or above were considered positive, high positive cows has
an S/P ratio of 30% or above, and negative cows never had an ELISA result over the S/P 20% threshold.
The calendar date of the first ELISA positive result was established for all Johne’s positive cows and
was used to identify a matched control cow. The pairing within the herd was first done by parity,
and when multiple controls were available, the cow with the closest calving date was selected.
For each ELISA positive cow and its paired control, individual mobility scores were assessed,
using the AHDB Dairy 0–3 system; cows with a score 2 or 3 were considered as lame. Cows were
considered chronically lame if they had two or more subsequent lame recordings on mobility scores.
Based on the date of turning ELISA positive, it was determined whether cows were lame before or
after this event.
2.2. Statistical Analysis
Data were entered into Microsoft Excel® for data analysis with statistical analysis performed
in GraphPad Prism® ((GraphPad Software, San Diego, California, USA)) and IBM SPSS Statistics®
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(IBM Corporation, Armonk, New York, USA). The statistical significance cut-off was set at p < 0.05.
The median parity was 3 at the point of seroconversion, and 22 months since first calving. The cows
were 219 days in milk (95% confidence interval: 173–266) at point of seroconversion.
A Kaplan Meier survival analysis was performed for all cows in the study, comparing ELISA
positive (S/P ratio >20%) cows with their matched controls. Date of entry was set at either date of first
calving or the beginning of mobility scorings on the farm, whichever was later. The hazard event
was set as the first lame score. The number of months was calculated to the hazard event for every
cow. Cows that did not have any event of lameness were right censored. GraphPad Prism® was used
to calculate survival times to first lameness and log rank hazard ratio of the ELISA positive group
compared to the control group. Log rank statistical testing was applied to compare the two curves.
We assessed whether the occurrence of lameness differed between Johne’s ELISA positive cows and
their controls; conditional logistic regression was performed to account for herd and parity matching.
In addition, to evaluate whether the lameness developed before or after the Johne’s seroconversion,
we ran logistic regression comparing the lameness rates pre- and post-seroconversion between the
medium and high positive cows. Farm and lactation number were forced into this model to account
for these factors. As a measure of magnitude of association, odds ratios (OR) and 95% confidence
intervals (CI) were calculated [28].
2.3. Ethical Approval
Informed consent was obtained from each farmer contributing to the study. The Clinical Research
and Ethical Review Board (CRERB) of the Royal Veterinary College, University of London has examined
and approved the research protocol (2016-U15).
3. Results
Overall, 98 ELISA positive cows were present on both farms. Of the ELISA positive cows, 49 had
a high positive (S/P > 30%) result and 49 were in the medium positive group (S/P 20–30%). The median
parity was 3 at the point of seroconversion, and 22 months since first calving. In total, 103 cows were
classed as lame during the study (Table 1), and 30 were classed as chronically lame.
The Kaplan Meier survival analysis indicated that median survival time (i.e., time from entry into
the study until the first lameness event) for the ELISA positive (S/P > 20%) and control group was 22
and 25 months, respectively. The survival curves are shown in Figure 1. Log rank statistical testing
applied to these survival curves revealed that there was a significant difference between the ELISA
positive cows and their controls, p = 0.010 (Figure 1). The log rank hazard ratio for the ELISA positive
group compared to control was 1.7 (95% CI = 1.1–2.6).
Figure 1. Time elapsed until the occurrence of a lameness event in cows diagnosed with Johne’s disease
compared to their lactation matched seronegative controls.
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Table 1. Number of lame and sound cows based on Johne’s status.
Lameness Status
Negative Cows
(n = 98)
(<20% S/P)
Medium Positive Cows
(n = 49)
(20% < S/P < 30%)
High Positive Cows
(n = 49)
(>30% S/P)
Lame cows
(of which chronic) 46 (13) 27 (10) 30 (7)
Before/after
Johne’s positive NA 13/14 9/21
Sound cows 52 22 19
NA: not applicable.
The conditional logistic regression showed that seropositive cows were more likely to be lame (OR
= 2.7 (95% CI = 1.2–6.0) p = 0.017). Looking specifically at the cows with a high serological response
(S/R ratio >30%), an even higher proportion of lameness was found compared to their matched controls
(OR = 3.6 (95% CI = 1.1–11.2), p = 0.029). The medium positive cows were, however, not different to
their controls regarding their lameness incidence (OR = 2.0 (95% CI = 0.6–6.2) p = 0.250).
A slightly higher number of cows that were ELISA positive had a chronic episode of lameness
than the control group, 17.3% (n = 17) compared to 13.3% (n = 13). Based on the conditional logistic
regression, the difference was not statistically significant, p = 0.160 with OR = 2.3 (95% CI = 0.7–7.0).
Of the seropositive cows, 35 cows turned lame after their first ELISA positive test, compared to
22 cows being lame before their first ELISA positive test. Comparing high positive cows to medium
positive, whilst controlling for farm and lactation number, there was not difference in the lameness
prevalence before seroconversion between the groups (p = 0.633). High positive cows were, however,
more likely to develop lameness after seroconversion (OR = 2.8 (95% CI = 1.1–7.5), p = 0.038), compared
to medium positive cows.
4. Discussion
It was observed that ELISA positive cows had a higher proportion of lameness and were 2.7
(S/R > 20%) or 3.6 (high seropositive) times more likely to be lame than the control group. These
findings have also been reported by Villarino and Jordan, who reported a slightly lower risk ratio
(1.67). In addition, on average, Johne’s positive cows go lame three months earlier than their matched
controls and at a similar time of seroconversion, both 22 months into their productive lives. The reason
for an increased level of lameness in Johne’s affected cows could be three-fold; through decreased
horn quality, increased NEB or reduced immune function. As NEB occurs at the start of the lactation,
and both the lameness and JD seroconversion in this study occurred toward the end, the NEB could be
a confounding factor that predisposes cows to developing both JD and lameness, through the impact
of an impaired immune response in cows with NEB.
Looking at the sequence of events, we found that the high JD-positive cows were more likely to be
lame after their first positive ELISA rather than before. Therefore, we can assume that Johne’s disease
predisposes cows to developing lameness. We do need to consider confounding factors, such as
NEB, which may predispose cows for both seroconversion and lameness development. The main
confounding factors for both lameness and JD seroconversion we have accounted for by the matching
on lactation number and days in milk of the case and control herd mates, leaving other factors, such as
milk yield and associated NEB, that could explain both events [29–31].
It is thought that cows with Johne’s disease are more prone to periods of severe NEB. It is still
uncertain if subclinical lesions are sufficient to cause reduced absorptive capacity and thus cause NEB,
but it is presumed that mild reductions in function are enough to increase the risk of severe NEB [13,18].
Seroconversion is associated with clinical progression, which is characterised by weight loss [32],
and cows with lower body condition scores (BCS) are predisposed to lameness [33,34]. During periods
of NEB, fat is mobilised from stores around the body. The digital cushion in cows consists partially of
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fat and is thought to be mobilised during NEB with the protective effects of the digital cushion on the
hoof being reduced [29]. In cows with Johne’s disease undergoing NEB, the digital cushion depletes
more quickly of fat and consequently increases the chance on lameness.
Johne’s disease has been thought to affect keratin quality in sheep (wool and horn) [35,36]; however,
evidence of this link is limited and conflicting [37,38]. In keratin, biotin has been shown to determine
the quality of the hooves [39–41], and biotin is absorbed in the small intestine, the primary lesion site
for JD. In humans, biotin supplementation is required in patients with short gut syndrome or other
causes of malabsorption [42]. Conceivably, cows with JD are not as efficient at absorbing biotin from
their diet and consequently have poorer quality hooves.
It has also been suggested that cows with JD have a reduced cellular immunity as a potential
explanation for increased mastitis and cell counts [16]. A reduced cellular immunity could make
seropositive cows more susceptible to infectious causes of lameness. Sadly, the cause of the lameness
was not recorded routinely on the farms that were studied, so the role of this potential explanation
cannot be fully explored. Neither did we measure the NEB, biotin levels or the cellular immunity of
our cows, as it was not the initial scope of this retrospective study. The current study suggests that
there is reason to include these in further studies, or indeed evaluate whether biotin supplementation
reduces the lameness in JD-positive cows more than in the average, JD-negative cow.
Johne’s disease and lameness have huge financial and welfare impacts on farms. The current
suggested temporal link suggests that the cost of JD may need to include the cost of lameness in the
dairy herd, at least partly. The economic burden to the UK dairy industry of lameness is rated at
£323 per case, and second only to mastitis [21,43] In addition, specific targeted interventions focusing
on reducing the impact of JD can be supported by the potential reduction of lameness cases and to
minimise losses and suffering.
5. Conclusions
The results from this investigation show that, controlled for farm and parity, Johne’s disease antibody
ELISA positive cows turn lame significantly earlier and are more likely to be lame than JD-negative cows.
High positive cows also have more lameness after the first ELISA positive result than cows that test medium
positive. The current study did not show a causal relationship between JD and lameness, but the (temporal)
association between the two conditions may help us to speculate on the development of each. Reasons for
the association could be Johne’s disease predisposing to lameness or both conditions having a common
underlying predisposing factor, such as a negative energy balance earlier in the lactation. Knowing the
relationship between the two conditions allows us to consider specific on-farm interventions to minimise
losses and reduce negative impacts of Johne’s disease on compromised welfare.
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